Acquired Company

AVROBIO completed the merger with Tectonic Therapeutic, Inc. on June 20, 2024, and the combined company began trading as TECX on Nasdaq.

Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein-coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts. Show more

490 Arsenal Way, Watertown, MA, 02472, United States

Biotechnology

Healthcare

Start AI Chat

Market Cap

396.6M

52 Wk Range

$13.70 - $30.58

Previous Close

$21.37

Open

$21.04

Volume

166,365

Day Range

$21.00 - $21.93

Enterprise Value

-78.05K

Cash

268.4M

Avg Qtr Burn

-17.82M

Insider Ownership

38.47%

Institutional Own.

74.34%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
TX45 Details Pulmonary hypertension in Heart failure with preserved Ejection Fraction (PH-HFpEF)	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TX45 Details Pulmonary hypertension in Heart failure with preserved Ejection Fraction (PH-HFpEF)	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TX45 Details Pulmonary Hypertension (PH) associated with Interstitial Lung Disease (ILD)	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TX2100 Details Hereditary Hemorrhagic Telangiectasia (HHT)	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.